Search clinical trials for: GDC-0980

Total 1899 results

Fundación Centro Nacional de Investigaciones Cardiovasculares...
Ferrer Internacional S.A.; Fundacion Clinic per a la Recerca Biomédica; World... and other collaborators

Completed

Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. (FOCUS)

Myocardial Infarction

Spain, Italy, Argentina, Brazil, Paraguay
University of Chicago
National Cancer Institute (NCI); Multiple Myeloma Research Foundation

Active, not recruiting

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Plasma Cell Myeloma | Residual Disease

United States
Janssen Research & Development, LLC

Completed

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer... and other conditions

United States, Puerto Rico
Jonsson Comprehensive Cancer Center
Novartis; Seagen Inc.

Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
The Lymphoma Academic Research Organisation

Completed

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma (AMC-085)

HIV Infection | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | HIV-associated Hodgkin Lymphoma

France
National Cancer Institute (NCI)

Completed

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma

United States
University of Malaya

Recruiting

The Effect of Different Remineralizing Agents on White Spot Lesions and Dental Plaque During Orthodontic Retention

Orthodontic Appliance Complication

Malaysia
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Malignant Glioma | Metastatic Malignant Neoplasm in the Brain | Central Nervous System Lymphoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Medical Research Foundation, Oregon

Terminated

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

Prostate Carcinoma | Health Status Unknown

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Adult Brain Glioblastoma

United States
National Cancer Institute (NCI)

Withdrawn

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | t(11;14) Negative
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Kidney Cancer

United States
Eske Corporation S.A.C

Terminated

Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer

Breast Cancer Stage IV | Breast Cancer Stage IIIA | Breast Cancer, Stage IIIB

Peru
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Multiple Myeloma Research Consortium
Eli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaborators

Recruiting

Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

Relapsed Refractory Multiple Myeloma

United States
Mayo Clinic
Multiple Myeloma Research Foundation

Completed

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | t(11;14)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Recurrent Acute Myeloid Leukemia

United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Withdrawn

Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery

Glioblastoma
Universitätsklinikum Hamburg-Eppendorf
German Research Foundation; University Hospital Tuebingen

Completed

Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation (STIMBOX)

Cerebral Stroke

Germany
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
GlaxoSmithKline

Completed

HerpeVac Trial for Young Women

Herpes Simplex Infection

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Indolent Adult Non-Hodgkin... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
King Abdulaziz University

Completed

A Clinical Assessment of Glass Carbomer Cement

Dental Caries Class II
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Progesterone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Canada, Puerto Rico, Ireland
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
University Hospital, Basel, Switzerland
Novartis; Schweizerische Stiftung für die Erforschung der Muskelkrankheiten

Recruiting

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis

Polymyalgia Rheumatica (PMR) | Giant Cell Arteritis (GCA)

Switzerland
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); National Marrow Donor Program; Blood and Marrow...

Completed

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Multiple Myeloma

United States
Daniel M. Spielman
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Malignant Central Nervous System Neoplasm | Metastatic Malignant Neoplasm in the Central Nervous System

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

Glioblastoma

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
Population Health Research Institute

Completed

DIalysis Symptom COntrol-Restless Legs Syndrome Trial (DISCO-RLS)

Restless Legs Syndrome | End Stage Renal Disease

Canada
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID); Indiana University and other collaborators

Recruiting

Kuwa Free! - Live Free!

HIV Infections | Contraception | Drug-drug Interaction

Kenya
University of Nebraska
National Cancer Institute (NCI)

Recruiting

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage IA Pancreatic Cancer AJCC v6 and v7 | Stage IB Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic... and other conditions

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa)

Early Breast Cancer

France, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic and Lymphoid System Neoplasm | Cytomegaloviral Infection

United States
Aydin Adnan Menderes University

Completed

Comparative Evaluation of Salivary Bisphenol-A Levels in Patients With Fixed Lingual, Hawley and Vacuum-formed Retainers

Orthodontic Retention

Turkey
University Fernando Pessoa

Completed

NCCL Direct Composite Restoration Performance With Self-Etch and Multimode Adhesives (SEMMAP)

Dental Adhesives/Restorations Performance

Portugal
University of Washington
Genentech, Inc.

Recruiting

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma

United States, Canada
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States

Search clinical trials for: GDC-0980

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations